SIGN UP
LOG IN
MARKET
ALPN
ALPN
Alpine Immune Sc
NASDAQ
15.43
+0.36
+2.39%
Opening 10:31 11/29 EST
OPEN
15.30
PREV CLOSE
15.07
HIGH
15.55
LOW
14.84
VOLUME
252.97K
TURNOVER
0
52 WEEK HIGH
16.26
52 WEEK LOW
5.81
MARKET CAP
896.45M
P/E (TTM)
-12.1143
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALPN last week (1120-1124)?
Weekly Report · 2d ago
Alpine Immune Sc: [Amend]General statement of acquisition of beneficial ownership
Press release · 6d ago
Weekly Report: what happened at ALPN last week (1113-1117)?
Weekly Report · 11/20 11:44
Six Flags, Howard Hughes, and More Stocks See Action From Activist Investors
F9 investments holds 8.8% of the shares of flooring retailer ll flooring. H partners owns 13.7% of six flags entertainment's stock. Pershing square owns 36.1% of real estate developer howard hughes holdings. Alpine immune sciences has increased its stake in the biopharmaceutical firm.
Barron‘s · 11/18 00:44
RBC Capital Remains a Buy on Alpine Immune Sciences (ALPN)
TipRanks · 11/17 01:47
Promising Outlook for Alpine Immune Sciences: Buy Rating Justified by Povetacicept’s Potential in B-cell Mediated Diseases
TipRanks · 11/16 12:22
The Latest Analyst Ratings for Alpine Immune Sciences
Alpine immune sciences has 10 analysts rating the stock. These 10 analysts have an average price target of $21.6 versus the current price of $12.4. Alpine immune sciences has been rated by the same 10 analysts over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock .
Benzinga · 11/15 17:00
Alpine Immune Sciences Presents New Translational Data On Povetacicept In Systemic Lupus Erythematosus At American College Of Rheumatology Convergence 2023
Alpine immune sciences presented new translational data for povetacicept in systemic lupus erythematosus at the american college of rheumatology convergence 2023. Initiation of phase 2 sle study planned for 2h 2024. Povetacsicept superior to wild-type taci-fc and b-cell depletion in a preclinical model of lupus.
Benzinga · 11/15 14:09
About ALPN
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company's scientific platform uses a directed evolution process to convert native immune system proteins from the immunoglobulin super family (IgSF) into multi-targeted therapeutics capable of modulating the human immune system. The Company’s product candidates include ALPN-101, ALPN-202 and ALPN-303. ALPN-101 is a dual inducible T cell costimulator (ICOS) and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Its oncology program is ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer. ALPN-303 is a dual B-cell cytokine antagonist for the treatment of B-cell mediated diseases.
Webull offers Alpine Immune Sciences Inc stock information, including NASDAQ: ALPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.
You can practice and explore trading ALPN stock methods without spending real money on the virtual paper trading platform.